[
  {
    "ts": null,
    "headline": "Transcript : Johnson & Johnson Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10",
    "summary": "Presenter SpeechTimothy Anderson Okay. I think we're live. Thank you for joining us. And sorry for the few-minute delay. I'm Tim Anderson, a large-cap and U.S. pharma analyst and biotech analyst at...",
    "url": "https://finnhub.io/api/news?id=79256d9ae0ccbcbd148c6495a126b7d5a6a92673e724a8114f281398a9a475e2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744043100,
      "headline": "Transcript : Johnson & Johnson Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10",
      "id": 134406219,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Presenter SpeechTimothy Anderson Okay. I think we're live. Thank you for joining us. And sorry for the few-minute delay. I'm Tim Anderson, a large-cap and U.S. pharma analyst and biotech analyst at...",
      "url": "https://finnhub.io/api/news?id=79256d9ae0ccbcbd148c6495a126b7d5a6a92673e724a8114f281398a9a475e2"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s psoriatic arthritis therapy trial meets endpoints",
    "summary": "The trial involved biologic-naïve subjects who had not responded adequately to standard therapies.",
    "url": "https://finnhub.io/api/news?id=d067fa015d1d667e29b308fe1b16f7e8429e177736dee6d37e7d5159aa60117c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744024329,
      "headline": "J&J’s psoriatic arthritis therapy trial meets endpoints",
      "id": 133738614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The trial involved biologic-naïve subjects who had not responded adequately to standard therapies.",
      "url": "https://finnhub.io/api/news?id=d067fa015d1d667e29b308fe1b16f7e8429e177736dee6d37e7d5159aa60117c"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 675-point fall led by losses for Nike, Home Depot shares",
    "summary": "Dow's 675-point fall led by losses for Nike, Home Depot shares",
    "url": "https://finnhub.io/api/news?id=21f7e6db04ac2d0313d5eedcd1de78dd786ff5d88ff8f33f73f9d760c1bf6583",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744022760,
      "headline": "Dow's 675-point fall led by losses for Nike, Home Depot shares",
      "id": 133741237,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow's 675-point fall led by losses for Nike, Home Depot shares",
      "url": "https://finnhub.io/api/news?id=21f7e6db04ac2d0313d5eedcd1de78dd786ff5d88ff8f33f73f9d760c1bf6583"
    }
  },
  {
    "ts": null,
    "headline": "Book Review: 'No More Tears' scrutinizes the legacy of health giant Johnson & Johnson",
    "summary": "Health care giant Johnson & Johnson is one of the most well-known and respected brands, and its response to the 1982 tampering of Tylenol bottles that killed seven people is held up in business...",
    "url": "https://finnhub.io/api/news?id=93347a5e560eae703295e92a4c6f301380453a9b7cad9121d99dc4ac17b9e247",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744018025,
      "headline": "Book Review: 'No More Tears' scrutinizes the legacy of health giant Johnson & Johnson",
      "id": 133738297,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Health care giant Johnson & Johnson is one of the most well-known and respected brands, and its response to the 1982 tampering of Tylenol bottles that killed seven people is held up in business...",
      "url": "https://finnhub.io/api/news?id=93347a5e560eae703295e92a4c6f301380453a9b7cad9121d99dc4ac17b9e247"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Small Cap Growth Strategy Q1 2025 Commentary",
    "summary": "ClearBridge Small Cap Growth Strategy Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=0d05ee80576887f8a527e6fc394b8892dec4c03a3e0052f0f59e58bc6ee0b379",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744012800,
      "headline": "ClearBridge Small Cap Growth Strategy Q1 2025 Commentary",
      "id": 133737835,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0d05ee80576887f8a527e6fc394b8892dec4c03a3e0052f0f59e58bc6ee0b379"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - TREMFYA is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis",
    "summary": "SPRING HOUSE - Johnson & Johnson today announced that the TREMFYA Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its major secondary endpoint of reducing...",
    "url": "https://finnhub.io/api/news?id=558d01e114dcdcaafaade42cf2f1496d96fde0df6af51d4fc736ebb2c947d1de",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744009395,
      "headline": "Johnson & Johnson - TREMFYA is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis",
      "id": 133737411,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SPRING HOUSE - Johnson & Johnson today announced that the TREMFYA Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its major secondary endpoint of reducing...",
      "url": "https://finnhub.io/api/news?id=558d01e114dcdcaafaade42cf2f1496d96fde0df6af51d4fc736ebb2c947d1de"
    }
  }
]